No Data
No Data
Beijing Strong Biotechnologies, Inc. (300406.SZ) spent RMB 78.9738 million to repurchase 0.82% of its shares.
Beijing Strong Biotechnologies, Inc. (300406.SZ) announced that as of July 19, 2024, the company has repurchased its shares...
Beijing Strong Biotechnologies, Inc. (stock code 300406.SZ) has repurchased 0.5260% of the shares.
Beijing Strong Biotechnologies, Inc. (300406.SZ) announced on July 1st that as of June 30th, 2024, the company has repurchased a total of 3,095,000 shares through a repurchase special securities account using centralized competitive trading, accounting for 0.5260% of the company's current total share capital. The highest fill price was 19.00 yuan per share, the lowest fill price was 14.76 yuan per share, and the total transaction amount was RMB 52,646,829.00 (excluding transaction fees). This repurchase is in compliance with the company's repurchase plan and relevant laws and regulations.
Beijing Strong Biotechnologies, Inc. (300406.SZ) received 13 medical instrument registration certificates.
Beijing Strong Biotechnologies, Inc. (Stock code: 300406.SZ) released an announcement that on June 26th, 2024, the company received a Drug Administration Approval Letter issued by the Beijing Municipal Drug Administration for its Class 3 new drug-Fluorouracil and Oxaliplatin Injection.
Beijing Strong Biotechnologies, Inc. (stock code 300406.SZ): China MEHECO Group plans to increase shareholding by no less than 30 million yuan.
On June 25th, Gelunhui reported that Beijing Strong Biotechnologies, Inc. (300406.SZ) disclosed that China Meheco Group, a shareholder holding more than 5% of the shares (referred to as the "shareholding entity"), plans to increase the company's stocks through legal means such as centralized competitive trading and bulk trading from June 25th, 2024 to December 24th, 2024. The planned increase in the company's shareholding amount is no less than 30 million yuan (including the part already increased as of June 25th, 2024), and the required funds for the increase are self-owned.
Zhitong A Share Sale Restriction Release List|May 17
According to the Zhitong Finance App, the ban on restricted shares of 13 listed companies was lifted on May 17, with a total market value of about 20.077 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, restricted stock type, number of unbanned shares Shenzhen Sanda A000032, original shareholders placed 493 million, Lutai A000726 share incentives, 6.795 million, Guohai Securities 000750 issued additional A shares, original shareholders placed 352 million, Nasda002180 equity incentives, restricted circulation 1,154 million Jiujiang Biotech 300406 share incentives to limit sales and circulation 4076 million
Jiuqiang Biotech (300406.SZ) announced first-quarter results, net profit of 121 million yuan, an increase of 8.67%
Jiuqiang Biotech (300406.SZ) released its report for the first quarter of 2024, achieving operating income of 3.9 during the reporting period...
No Data